

Rajarshi Guha

National Center for Advancing Translational Science
9800 Medical Center Drive
Rockville, MD 20850

208 Saddle Hill Road
Manchester, CT 06040
Ph: (814) 404 5449

guhar@mail.nih.gov | [Blog](#) | [Google Scholar](#) | [ORCID](#)

Computational scientist with 10 years of experience in designing & implementing computational infrastructures and the development of novel algorithms for life sciences data with a focus on pre-clinical small molecule drug discovery. My track record is evidenced by multiple deployed systems and more than 100 publications in peer reviewed journals. I have co-written multiple federally funded grants worth more than \$2M. In addition I have extensive experience in public speaking, with more than 30 invited talks, as well as teaching workshops and classes at the graduate & undergraduate levels.

My goal is to impact therapeutic development by designing scalable computational methodologies that integrate heterogenous data types from multiple biological scales, to generate a global picture of the effects of small molecules in biological systems. I am particularly interested in linking chemical structure information to molecular, bibliographic genomic and clinical covariates to enable the study of polypharmacology and repurposing.

Professional Experience

- 01/01/2017 – ... • Editor in Chief, *J. Cheminformatics*
- 07/01/2009 – ... • Informatics Scientist, National Center for Advancing Translational Science, NIH
- 07/01/2009 – ... • Adjunct Professor, School of Informatics, Indiana University
- 08/01/2007 – 06/31/2009 • Visiting Assistant Professor, School of Informatics, Indiana University
- 08/01/2006 – 07/30/2007 • Post-doctoral scholar working with Prof. D. Wild at Indiana University
- 08/01/2005 – 07/30/2006 • Post-doctoral scholar working with Prof. P. C. Jurs, Pennsylvania State University

Education

- 07/01/2001 – 07/30/2005 • Ph.D. (Chemistry), Department of Chemistry, The Pennsylvania State University.
- 05/01/1999 – 06/30/2001 • M.Sc. (Chemistry), Indian Institute of Technology, Kharagpur, India.
- 08/01/1995 – 07/30/1998 • B.Sc. (Chemistry), Presidency College, Calcutta, India.

Leadership & Mentoring

- Led the development and writing of the NCATS portion of two major grant applications ([BARD](#) and [IDG Pharos](#)) worth more than \$2M
- Led the development of the complete informatics and analytic infrastructure underlying two key NCATS initiatives - the Trans NIH-RNAi Screening Facility & the NCATS Combination Screening Platform
- Developed and taught workshops on R for biologists at NCATS and EBI (Hinxton, UK) and involved in scientific mentoring of interns within the Informatics group
- Chair (2012) and Vice Chair (2011), ACS Division of Chemical Information
- Program Chair (2009-2010) and Asst. Program Chair (2007-2009), ACS Division of Chemical Information

Leadership & Mentoring (continued)

- Co-founder of the Blue Obelisk group, to promote Open Data, Open Source and Open Standards within chemistry. See [Guha et al, 2006](#) & [O'Boyle et al, 2011](#).
- Member of the editorial boards of Chemistry Central Journal, Current Computer Aided Drug Design, Journal of Cheminformatics and Synergy
- Organizer or co-organizer for multiple symposia at ACS National Meetings including *Scripting & Programming* (Fall 2009), *Systems Chemical Biology: Integrating Chemistry and Biology for Network Models* (Fall 2008) and *Cheminformatics Techniques in Bioinformatics* (Fall 2007)

Research & Development Experience

- 2009 – ...
- My duties at NCATS have ranged from infrastructure development for major center-wide initiatives as a well project specific algorithm development. Much of work has been collaborative and has required me to identify optimal solutions and achieve consensus amongst a variety of stakeholders.

I led the development of the NCATS portions of Pharos, a user interface to the Knowledge Management Center of the Illuminating the Druggable Genome project and the BioAssay Research Database (BARD), a next generation chemical biology database. In both cases, I laid out the roadmap and designed the high level architecture of the systems and was responsible for maintaining the development schedule and interactions with our external collaborators.

I have been responsible for the entire data management, visualization & analysis pipeline for the NCATS high throughput combination screening platform. Prior to this I developed the informatics infrastructure for the Trans-NIH RNAi Screening facility. I have been instrumental in providing informatics support for high content screening projects, ranging from image analysis to informatics pipelines for the vendor integration, image storage and management and data mining methods.

In parallel with infrastructure development, I have worked on a variety of more focused, problem specific areas. These include support for chemical probe development projects, including cherry picks, lead optimization and general cheminformatics analysis. Biologies covered include infectious disease, neurodegeneration and cancers.

Recently I have been exploring approaches to mine large scale combination screening datasets. These include network models that allow one gain insight from large all-pair combination datasets and a novel similarity kernel that allows us to compare cell lines in “combination space”. I also have ongoing efforts to develop and refine methods for the analysis of small molecule datasets from a variety of viewpoints - structure-activity landscapes, polypharmacology & promiscuity and scaffold based analyses that allow efficient summarization of large chemical datasets.

- 2007 – 2009
- Extended work on density of chemical space by using the *R*-NN method applied to compound selection in combinatorial libraries. I continued working on methods for handling large chemical datasets, including predictive modeling of HTS cytotoxicity data, virtual screening and QSAR modeling of large combinatorial libraries for anti-malarial activity and implementation of a fast 3D searching and pharmacophore matching in very large compound databases. During this period, I examined methods to characterize activity landscapes and proposed approaches to explore promiscuity and polypharmacology in PubChem bioassays using network models.

Research & Development Experience (continued)

- 2005 – 2007
- Implemented web service infrastructure to deploy integrated statistical and cheminformatics environments. Developed algorithm development for feature selection, analysis of large chemical spaces with applications to diversity analysis and clustering. Collaborated with Procter & Gamble to implement automated QSAR pipelines

Awards

- 2016
- NIH Directors Award (Malaria Combination Screening)
- 2015
- NIH Directors Award (Ebola Drug Repurposing)
- 2015
- Corwin-Hansch Award
- 2013
- NIH Directors Award (Malaria Screening)
- 2012
- Kelly Distinguished Performance Award
- 2011
- NIH Directors Award (Trans-NIH RNAi Screening)
- 2010
- Kelly Distinguished Performance Award
- 2007
- Jacques-Emile Dubois Grant Pennsylvania State University.

Computing & Data Science Experience

- Languages
- Extensive experience with Java, Python, C and Unix shell scripting. Familiar with C++, Fortran and Lisp.
 - Extensive experience with R for modeling and algorithm prototyping. Published and maintain packages that incorporate cheminformatics within R, handle molecular fingerprint data and interface R to the PubChem & ChEMBL bioassay and compound collections. Extended support for PMML in R
- Platforms
- 10 years experience in developing J2EE based REST API's and clients using industry standard technology stacks. Experienced user of the OpenEye & ChemAxon toolkits, familiar with Pipeline Pilot, KNIME.
- Databases
- Extensive experience with traditional RDBMS (Oracle, MySQL and PostgreSQL) and no-SQL databases (MongoDB), as well as integration of chemistry with databases

Memberships

- Member of the editorial boards of *Chemistry Central Journal*, *J. Cheminformatics* and *Curr. Drug Discov. Tech.*
- Member of the Scientific Advisory Board for the International Conference on Chemical Structures
- Member of the American Chemical Society

Publications

109. ● Kalantat-Motamedi, Y.; Eastman, R.T.; **Guha, R.**; Bender, A.; “A systematic and prospectively validated approach for identifying synergistic drug combinations against malaria”, *Malaria J.*, **submitted**, ,
108. ● Calabrese, D.R.; Zlotkowski, K.; Alden, S.; Hewitt, W.M.; Connelly, C.M.; Wilson, R.M.; Gaikwad, S.; Chen, L.; **Guha, R.**; Thomas, C.J.; Mock, B.; Schneekloth, J.S.; “Small Molecule Microarray Profiling Reveals FDA Approved Drugs that Target the KRAS G-Quadruplex”, *Angewandte Chemie*, **submitted**, ,
107. ● Yohe, M.E.; Gryder, B.E.; Shern, J.F.; Chou, H.C.; Song, Y.K.; Liao, H.; Sindiri, S.; Mendoza, A.; Zhang, X.; **Guha, R.**; Haines, D.C.; Mathews-Griner, L.A.; Li, S.Q.; Ferrer, M.; Thomas, C.J.; Khan, J.; “Epigenetic Reprogramming of RAS-driven Rhabdomyosarcoma via MEK Inhibition”, **2017**, submitted
106. ● Wang, S.; Hwang, E.E.; **Guha, R.**; O’Neill, A.F.; Melong, N.Veinotte.; Saur, A.C.; Shen, M.; McKnight, C.; Alexe, G.; Lemieux, M.E.; Wang, A.; Hughes, E.; Xu, X.; Boxer, M.B.; Hall, M.D.; Kung, A.; Berman, J.N.; Davis, M.I.; Stegmaier, K.; Crompton, B.D.; “High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma”, **2017**, submitted
105. ● Oprea, T.I.; Bologa, C.G.; Brunak, S.; Campbell, A.; Gan, G.N.; Gaulton, A.; Gomez, S.M.; **Guha, R.**; Hersey, A.; Holmes, J.; Jadhav, A.; Jensen, L.J.; Johnson, G.L.; Karlson, A.; Leach, A.R.; Ma’ayan, A.; Malovannaya, A.; Mani, S.; Mathias, S.L.; McManus, M.T.; Meehan, T.F.; Mering, C.V.; Nguyen, D.; Overington, J.P.; Papadatos, G.; Qin, J.; Reich, C.; Schürer, S.C.; Simeonov, A.; Sklar, L.A.; Southall, N.; Tomita, S.; Tudose, I.; Ursu, O.; Vidović, D.; Waller, A.; Yang, J.J.; Zahoranzky-Köhalmi, G.; “Unexplored Therapeutic Opportunities in the Human Genome”, **2017**, submitted
104. ● McKinnon, T.; Venier, R.; Yohe, M.; Sindiri, S.; Gryder, B.; F., J.; Kabaroff, L.; Dickson, B.; Schleicher, K.; Chouinard-Pelletier, G.; Menezes, S.; Gupta, A.; Zhang, X.; **Guha, R.**; Ferrer, M.; Thomas, C.; Wei, Y.; Davani, D.; Guidos, C.; Khan, J.; Gladly, R.; “PI3K/mTOR inhibition as a therapeutic strategy in FGFR4-driven rhabdomyosarcoma”, *J. Clin. Invest.*, **2017**, submitted
103. ● Mason, D.J.; Eastman, R.T.; **Guha, R.**; Lewis, R.P.I.; Stott, I.P.; Bender, A.; “The prediction of synergistic antimalarial drugs based upon known compound structure”, **2017**, submitted
102. ● Jansson, K.; Tucker, J.; Stahl, L.; Simmons, J.; Fuller, C.; Beshiri, M.; Agarwal, S.; Fang, L.; Hynes, P.; Alilin, A.; Cawley, J.; Lake, R.; Tran, C.; Tice, C.; Yin, J.; Zhang, X.; **Guha, R.**; Hoover, S.; Simpson, R.; Nguyen, H.; Corey, E.; Thomas, C.; Proia, D.; Kelly, K.; “High-throughput screen identifies HSP90 inhibitor efficacy across clinically-representative organoid models of advanced prostate cancer”, *Clin. Cancer. Res.*, **2017**, submitted
101. ● Ferrer, M.; Gosline, S.J.C.; Stathis, M.; Zhang, X.; Guo, X.; **Guha, R.**; Ryman, D.; Wallace, M.; Kasch-Semenza, L.; Hao, H.; Ashworth, R.; Ling, H.; Thomas, C.; Verma, S.; Guinney, J.; Blakeley, J.O.; “Pharmacological profiling and genomic characterization of human derived neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells”, **2017**, submitted
100. ● Feliz-Mosquea, Y.; Christensen, A.; Cook, K.; Schwartz, A.; Chen, Q.R.; Griner-Mathews, L.; **Guha, R.**; Thomas, C.; Ferrer, M.; Merino, M.J.; Roberts, D.; Pantoja, D.S.; “Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy”, **2017**, submitted
99. ● Zdrazil, B.; **Guha, R.**; “The rise and fall of a scaffold: A trend analysis of scaffolds in the medicinal chemistry literature”, *J. Med. Chem.*, **2017**, in press

Publications (continued)

98. • Gladdy, R.; McKinnon, T.; Venier, R.; Yohe, M.; Sindiri, S.; Gryder, B.; Shern, J.; Kabaroff, L.; Dickson, B.; Schleicher, K.; Chouinard-Pelletier, G.; Menezes, S.; Gupta, A.; Zhang, X.; **Guha, R.**; Ferrer, M.; Thomas, C.; Wei, Y.; Davani, D.; Guidos, C.; Khan, J.; “Functional Screening of FGFR4 Driven Tumorigenesis Identifies PI3K/mTOR Inhibition as an Effective Therapeutic Strategy in Rhabdomyosarcoma”, *Oncogene*, **2017**, in press
97. • Willighagen, E.L.; May, J.W.; Alvarsson, J.; Berg, A.; Carlsson, L.; Duhrkop, K.; Jeliaskova, N.; Kuhn, S.; Pluskal, T.; Rojas-Cherto, M.; Spjuth, O.; Torrance, G.; Evelo, C.T.; **Guha, R.**; Steinbeck, C.; “The Chemistry Development Kit (CDK): atom typing, rendering, molecular formulas, and substructure searching”, *J. Cheminf.*, **2017**, *9*,
96. • **Guha, R.**; Willighagen, E.L.; “Helping to improve the practice of cheminformatics”, *J. Cheminf.*, **2017**, *9*,
95. • Lin, Y.; Mehta, S.; McGinty, H.K.; Turner, J.P.; Vidovic, D.; Forlin, M.; Koleti, A.; Nguyen, D.-T.; Jensen, L.J.; **Guha, R.**; Mathias, S.; Ursu, O.; Stathias, V.; Duan, J.; Nabizadeh, N.; Chung, C.; Mader, C.; Visser, U.; Yang, J.Bologa.; Oprea, T.I.; Schürer, S.C.; “Drug Target Ontology to Classify and Integrate Drug Discovery Data”, *J. Biomed. Semantics*, **2017**, *8*,
94. • Gryder, B.E.; Yohe, M.E.; Chou, H.C.; Zhang, X.; Song, Y.; Marques, J.; Schaefer, B.; Sen, N.; Patidar, R.; Wen, X.; Wei, J.; **Guha, R.**; Ferrer, M.; Lal-Nag, M.; Andresson, T.; Shern, J.F.; Zhao, K.; Thomas, C.J.; Khan, J.; “PAX3-FOXO1 establishes myogenic super enhancers and confers BET bromodomain vulnerability”, *Cancer Discov.*, **2017**, *7*, 884–899
93. • Nguyen, D.-T.; Mathias, S.; Bologa, C.; Brunak, S.; Fernandez, N.; Gaulton, A.; Hersey, A.; Holmes, J.; Jensen, L.J.; Karlsson, A.; Lu, G.; Mayan, A.; Mandava, G.; Mani, S.; Mehta, S.; Overington, J.P.; Patel, J.; Rouillard, A.D.; Schurer, S.; Sheils, T.; Simeonov, A.; Sklar, L.; Southall, N.; Ursu, O.; Vidovic, D.; Waller, A.; J., Y.; Jadhav, A.; Oprea, T.I.; **Guha, R.**; “Pharos: Collating Protein Information to Shed Light on the Druggable Genome”, *Nucl. Acids Res.*, **2017**, *45*, D995–D1002
92. • Heske, C.; Davis, M.; Baumgart, J.; Wilson, K.; Gormally, M.; Chen, L.; Zhang, X.; Ceribelli, M.; Duveau, D.; **Guha, R.**; Ferrer, M.; Arnaldez, F.; Ji, J.; Tran, H.; Zhang, Y.; Mendoza, A.; Helman, L.; Thomas, C.; “Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma”, *Clin. Cancer Res.*, **2017**, *23*, 7301–7311
91. • Chen, I.; Mathews-Greiner, L.; Li, D.; Abisoye-Ogunniyan, A.; Ray, S.; Bian, Y.; Shukla, V.; Zhang, X.; **Guha, R.**; Thomas, C.; Gryder, B.; Zacharia, A.; Beane, J.D.; Ravichandran, S.; Ferrer, M.; Rudloff, U.; “Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer”, *J. Translat. Med.*, **2017**, *15*, 92
90. • Nelson, E.A.; Dyall, J.; Hoenen, T.; Barnes, A.B.; Zhou, H.; Liang, J.Y.; Michelotti, J.; Dewey, W.H.; DeWald, L.E.; Bennett, R.S.; Morris, P.J.; **Guha, R.**; Klumpp-Thomas, C.; McKnight, C.; Chen, Y.; Xu, X.; Wang, A.; Hughes, E.; Martin, S.; Thomas, C.; Jahrling, P.B.; Hensley, L.E.; Olinger, G.G.; White, J.M.; “The Phosphatidylinositol-3-phosphate 5-kinase Inhibitor Apilimod Blocks Filoviral Entry and Infection”, *PLoS Neglected Trop. Dis.*, **2017**, *11*, 1–22
89. • Iniguez, A.B.; Alexe, G.; Wang, E.J.; Roti, G.; Patel, S.; Chen, L.; Kitara, S.; Conway, A.; Stolte, B.; Bandopadhyay, P.; Goodale, A.; Hall, M.; **Guha, R.**; Cheff, D.; Davis, M.; Qi, J.; Beroukhim, R.; Piccioni, F.; Johannessen, C.; Stegmaier, K.; “Enhancer remodeling promotes resistance to epigenetic-targeted therapy and engenders tumor cell vulnerabilities”, *submitted*, **2017**, ,

Publications (continued)

88. • Lal-Nag, M.; McGee, L.; **Guha, R.**; Lengyel, E.; Kenny, H.A.; Ferrer, M.; “A high throughput screening model of the tumor microenvironment for ovarian cancer cell growth”, *SLAS Discovery*, **2016**, in press
87. • Serra-Musach, J.; Mateo, F.; Capdevila-Busquets, E.; Zhang, X.; **Guha, R.**; Thomas, C.; Gruseo, J.; Ruiz de Garibay, G.; Villaneuva, A.; Gustafsson, M.; Benson, M.; Jaeger, S.; Heyn, H.; Vizoso, M.; Perez, H.; Cordero, A.; Gonzalez-Suarez, E.; Esteller, M.; Moreno-Bueno, G.; Lazaro, C.; Serra, V.; Arribas, J.; Ferrer, M.; Aloy, P.; Pujana, M.A.; “Cancer network activity associated with therapeutic response and synergism”, *Genome Medicine*, **2016**, *8*, 1–12
86. • Mathews-Griner, L.A.; Zhang, X.; **Guha, R.**; McKnight, C.; Goldlust, I.S.; Lal, M.; Wilson, K.; Michael, S.; Titus, S.; Shinn, P.; Thomas, C.; Ferrer, M.; “Large Scale Pharmacological Profiling of 3D Tumor Models of Cancer Cells”, *Cell Death & Disease*, **2016**, *7*, e2492
85. • Anantpadma, M.; Kouznetsova, J.; Wang, H.; Huang, R.; **Guha, R.**; Lindstrom, A.; Shtanko, O.; Simeonov, A.; Maloney, D.J.; Maury, W.; LaCount, D.; Jadhav, A.; Davey, R.; “Large Scale Screening and Identification of Novel Ebolavirus and Marburgvirus Entry Inhibitors”, *Antimicrobial Agents and Chemotherapy*, **2016**, *60*, 4471–4481
84. • Chen, L.; Wilson, K.; Goldlust, I.S.; Mott, B.T.; Eastman, R.T.; Davis, M.I.; Zhang, X.; McKnight, C.; Klumpp-Thomas, C.; Shinn, P.; Simmons, J.; Gormally, M.; Michael, S.; Thomas, C.J.; Ferrer, M.; **Guha, R.**; “mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening”, *Sci. Rep.*, **2016**, *6*, 1
83. • Ceribelli, M.; Kelly, P.N.; Ganapathi, K.; Evbuomwan, M.; Stefania, P.; Shaffer, A.L.; Wright, G.; Xiao, W.; **Guha, R.**; Zhang, X.; Ferrer, M.; Hou, E.Z.; Jaffe, E.S.; Reizis, B.; Thomas, C.; Staudt, L.M.; “A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm”, *Cancer Cell*, **2016**, *30*, 764–778
82. • **Guha, R.**; Mathews-Griner, L.A.; Keller, J.; Fitzgerald, D.J.; Atignani, A.; Pastan, I.; Thomas, C.J.; Ferrer, M.; “Ranking Differential Drug Activities from Dose Response Synthetic Lethality Screens”, *J. Biomol. Screen.*, **2016**, *21*, 942–955
81. • Baranello, L.; Wojtowicz, D.; Kouzine, F.; Cui, K.; Chan-Salis, K.Y.; Devaiah, B.; Wilson, K.; **Guha, R.**; Thomas, C.; Singer, D.; Pommier, Y.; Pugh, B.F.; Przytyka, T.M.; Lewis, B.A.; Zhao, K.; Levens, D.; “RNA Polymerase II Regulates Topoisomerase 1 Activity to Favor Efficient Transcription”, *Cell*, **2016**, *165*, 357–371
80. • Van Voorhis, W.C. et al; “Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond”, *PLoS Pathogens*, **2016**, *12*, e1005763
79. • Jun, W.; Zhang, M.; Wilson, K.; Petrus, M.N.; Bamford, R.; Zhang, X.; **Guha, R.**; Ferrer, M.; Thomas, C.; Waldmann, T.A.; “Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin’s Lymphoma”, *Proc. Nat. Acad. Sci.*, **2016**, *113*, 1624–1629
78. • Cong, Y.; Dyall, J.; Hart, B.J.; DeWald, L.E.; Johnson, J.C.; Postnikova, E.; Zhou, H.; Gross, R.; Rojas, O.; Alexander, I.; Josleyn, N.; Zhang, T.; Michelotti, J.; Janosko, K.; Honko, A.; Holbrook, M.; Bennett, R.S.; Olinger, G.O.; Glass, P.J.; Thomas, C.; Mierzwa, T.; **Guha, R.**; Shinn, P.; Michael, S.; Klumpp-Thomas, K.; McKnight, C.; Hensley, L.; Jahrling, P.B.; “Evaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus In Vitro and In Vivo”, *PLoS One*, **2016**, *11*, e0166318

Publications (continued)

77. • Antignani, A.; Mathews Griner, L.; **Guha, R.**; Simmon, N.; Pasetto, M.; Keller, J.; Huang, M.; Angelus, E.; Pastan, I.; Ferrer, M.; FitzGerald, D.; Thomas, C.; “Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-toxin fusion proteins”, *PLoS One*, **2016**, *11*, e0161415
76. • Cheng, K.Chih-Chien.; Cao, S.; Raveh, A.; MacArthur, R.; Dranchak, P.; Chlipala, G.; Okoneski, M.T.; **Guha, R.**; Eastman, R.T.; Yuan, J.; Schultz, P.J.; Su, X.; Tamayo-Castillo, G.; Matainaho, T.; Clardy, J.; Sherman, D.H.; Inglese, J.; “Actinoramide A stereoisomer identified as potent anti-malarial from titration-based screening of marine natural product extracts”, *J. Nat. Prod.*, **2015**, *78*, 2411–2422
75. • Lewis, R.; **Guha, R.**; Korcsmaros, T.; Bender, A.; “Synergy Maps: Exploring compound combinations using network-based visualization”, *J. Cheminf.*, **2015**, *7*,
74. • Bogen, D.; Wei, J.S.; Azorsa, D.O.; Ormanoglu, P.; Buehler, E.; **Guha, R.**; Keller, J.M.; Mathews-Griner, L.A.; Ferrer, M.; Song, Y.K.; Liao, H.; Mendoza, A.; Gryder, B.E.; Sindri, S.; He, J.; Wen, X.; Zhang, S.; Shern, J.F.; Yohe, M.E.; Taschner-Mandl, S.; Shohet, J.M.; Thomas, C.J.; Martin, S.E.; Ambros, P.F.; Khan, J.; “Aurora B Kinase is a Potent and Selective Target in MYCN-driven Neuroblastoma”, *Oncotarget*, **2015**, *6*, 35247–35262
73. • Mott, B.T.; Eastman, R.T.; **Guha, R.**; Sherlach, K.S.; Siriwardana, A.; Shinn, P.; McKnight, C.; Michael, S.; Lacerda-Quieroz, N.; Patel, P.R.; Khine, P.; Sun, H.; Kasbeka, M.; Aghdam, N.; Fontaine, S.D.; Liu, D.; Mierzwa, T.; Mathews-Griner, L.A.; Ferrer, M.; Renslo, A.R.; Inglese, J.; Yuan, J.; Roepe, P.D.; Su, X.; Thomas, C.J.; “High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations”, *Scientific Reports*, **2015**, *5*,
72. • Lewi, K.; Nair, A.; Railkar, R.; Brancato, S.; Hsu, I.; Li, Q.; Zhang, X.; **Guha, R.**; Apolo, A.; Theodorescu, D.; “MP68-17 Novel Intravesical Therapies Identified from High Throughput Screening”, *J. Urology*, **2015**, *193*, e864–e865
71. • Zhang, M.; Mathews-Griner, L.A.; Ju, W.; DuvEAU, D.; **Guha, R.**; Petrus, M.N.; Wen, B.; Maeda, M.; Shinn, P.; Ferrer, M.; Conlon, K.D.; Bamford, R.; Oshea, J.; Thomas, C.J.; Waldmann, T.A.; “Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia”, *Proc. Nat. Acad. Sci.*, **2015**, *112*, 12480–12485
70. • Pasetto, M.; Antignani, A.; Ormanoglu, P.; Buehler, E.; **Guha, R.**; Pastan, I.; Fitzgerald, D.J.; “A whole genome RNAi screen highlights components of the ER/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity”, *Proc. Nat. Acad. Sci.*, **2015**, *112*, 1135–1142
69. • Lee, J.A.; Shinn, P.; Jaken, S.; Oliver, S.; Willard, F.S.; Heidler, S.; Peery, R.B.; Oler, J.; Chu, S.; Southall, N.; Dexheimer, T.S.; Smallwood, J.; Huang, R.; **Guha, R.**; Jadhav, A.; Cox, K.; Austin, C.P.; Simeonov, A.; Sittampalam, G.Sitta.; Husain, S.; Franklin, N.; Wild, D.J.; Yang, J.J.; Sutherland, J.J.; Thomas, C.J.; “Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays”, *PLoS ONE*, **2015**, *10*, e0130796 EP –
68. • Hasson, S.; Fogel, A.I.; Wang, C.; MacArthur, R.; **Guha, R.**; Heman-Ackah, S.; Martin, S.E.; Youle, R.J.; Inglese, J.; “Chemogenomic profiling of endogenous PARK2 expression using a genome-edited coincidence reporter”, *ACS Chem. Biol.*, **2015**, *10*, 1188–1197
67. • Bulusu, K.C.; **Guha, R.**; Mason, D.J.; Lewis, R.; Muratov, E.; Kalantat-Motamedi, Y.; Cokol, M.; Bender, A.; “Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives”, *Drug. Discov. Today*, **2015**, ,

Publications (continued)

66. • Carver, J.; Dexheimer, T.S.; Hsu, D.; Weng, M.T.; **Guha, R.**; Jadhav, A.; Simeonov, A.; Luo, J.; “A high-throughput assay for small molecule destabilizers of the KRAS oncoprotein”, *PLoS One*, **2014**, *9*, e103836
65. • Inglese, J.; Dranchak, P.; Moran, P.; Jang, S.-W.; Cost, G.J.; Srinivasan, R.; **Guha, R.**; Martinez, N.; MacArthur, R.; Urnov, F.D.; Svaren, J.; “Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-Tooth disease”, *ACS Chem. Biol.*, **2014**, *9*, 2594–2602
64. • Josse, R.; S.E., M.; **Guha, R.**; Ormanoglu, P.; Pfister, T.; Morris, J.; Doroshow, J.; Pommier, Y.; “ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase I inhibitors by disabling DNA replication initiation and fork elongation responses”, *Cancer Res.*, **2014**, *74*, 6968–6979
63. • **Guha, R.**; Medina-Franco, J.L.; “On the Validity versus Utility of Activity Landscapes: Are All Activity Cliffs Statistically Significant?”, *J. Cheminf.*, **2014**, *6*,
62. • Howe, E.; de Souza, A.; Lahr, D.; Chatwin, S.; Montgomery, P.; Alexander, B.; Nguyen, D.-T.; Cruz, Y.; Stonish, D.; Walzer, G.; Jason, R.; Picard, S.; Liu, Z.; Rose, J.; Xiang, X.; Asiedu, J.; Durkin, D.; Levine, J.; Yang, J.; Schürer, S.; Braisted, J.; Southall, N.; Southern, M.; Chung, T.D.Y.; Brudz, S.; Tanega, C.; Schreiber, S.L.; Bittker, J.; **Guha, R.**; Clemons, P.; “BioAssay Research Database (BARD): Chemical biology and probe-development enabled by structured metadata and result types”, *Nucl. Acids Res.*, **2014**, *43*, D1163–D1170
61. • de Souza, A.; Bittker, J.; Lahr, D.; Brudz, S.; Chatwin, S.; Oprea, T.I.; Waller, A.; Yang, A.; Southall, N.; **Guha, R.**; Schurer, S.; Vempati, U.; Southern, M.R.; Dawson, E.S.; Clemons, P.A.; Chung, T.D.Y.; “An overview of the challenges in designing, integrating, and delivering BARD: A public chemical-biology resource and query portal for multiple organizations, locations, and disciplines”, *J. Biomol. Screen.*, **2014**, *19*, 614–627
60. • Ceribelli, M.; Priscilla, K.; Shaffer, A.L.; Wright, G.; Yang, Y.; Mathews-Griner, L.A.; **Guha, R.**; Shinn, P.; Keller, J.M.; Liu, D.; Patel, P.R.; Ferrer, M.; Joshi, S.; Nerle, S.; Sandy, P.; Normant, E.; Thomas, C.J.; Staudt, L.M.; “Blockade of oncogenic I κ B kinase activity in ABC DLBCL by small molecule BET protein inhibitors”, *Proc. Natl. Acad. Sci.*, **2014**, *111*, 11365–11370
59. • Mathews, L.; **Guha, R.**; Shinn, P.; Young, R.A.; Keller, J.; Liu, D.; Goldlust, I.S.; Yasgar, A.; McKnight, C.; Boxer, M.B.; DuvEAU, D.; Jiang, J.K.; Michael, S.; Mierzwa, T.; Huang, W.; Walsh, M.J.; Mott, B.T.; Patel, P.R.; Leister, W.; Maloney, D.J.; LeClair, C.A.; Rai, G.; Jadhav, A.; Peyser, B.D.; Austin, C.P.; Martin, S.; Simeonov, A.; Ferrer, M.; Staudt, L.M.; Thomas, C.J.; “High-throughput combinatorial screening identifies drugs that cooperate with Ibrutinib to kill ABC Diffuse Large B Cell Lymphoma cells”, *Proc. Nat. Acad. Sci.*, **2014**, *111*, 2349–2354
58. • Casson, L.; Howell, L.; Mathews, L.A.; Ferrer, M.; Southall, N.; **Guha, R.**; Keller, J.M.; Thomas, C.; Varmus, H.; Siskind, L.J.; Beverly, L.J.; “Inhibition of Ceramide Metabolism Sensitizes Human Leukemia Cells to Inhibition of BCL2-like Proteins”, *PLoS One*, **2013**, *8*, e54525
57. • Dranchak, P.; MacArthur, R.; **Guha, R.**; Zuercher, W.J.; Drewry, D.H.; Auld, D.S.; Inglese, J.; “Profile of the GSK published protein kinase inhibitor set across ATP-dependent and-independent luciferases: Implications for reporter-gene assays”, *PLoS One*, **2013**, *8*,
56. • Hasson, S.; Kane, L.; Sliter, D.; Hessa, T.; Wang, C.; Buehler, E.; **Guha, R.**; Martin, S.; Yamano, K.; Huang, C.H.; Heman-Ackah, S.; Youle, R.; “Genome-wide high-content RNAi screens identify regulators of Parkin upstream of mitophagy”, *Nature*, **2013**, *504*, 291–295
55. • Ghosh, D.; **Guha, R.**; “What are we ”tweeting” About Obesity? Mapping Tweets with Topic Modeling and Geographic Information System”, *Cartography and GIS*, **2013**, *4*, 90–102

Publications (continued)

54. ● Redan, B.W.; Motobar, O.; Tuzmen, P.; **Guha, R.**; Caplen, N.J.; S.E., M.; “RNAi Screen Reveals Candidate miRNAs Associated with the NF-kappaB Pathway”, *FASEB J.*, **2013**, *27*, 780–781
53. ● Rhyasen, G.W.; Bolanos, L.; Fang, J.; Rasch, C.; Jerez, A.; Varney, M.; Wunderlicj, M.; Rigolino, C.; Mathews, L.; Ferrer, M.; Southall, N.; **Guha, R.**; Keller, J.; Thomas, C.; Beverly, L.J.; Agostino, C.; Oliva, E.N.; Cuzzola, M.; Maciejewski, J.P.; Mulloy, J.C.; Starczynowski, D.T.; “Targeting IRAK1 as a Novel Therapeutic Approach for Myelodysplastic Syndrome”, *Cancer Cell*, **2013**, *24*, 90–104
52. ● Druz, A.; Chen, Y.C.; **Guha, R.**; Betenbaugh, M.; Martin, S.; Shiloach, J.; “Large-Scale Screening Identifies a Novel microRNA, miR-15a-3p, which Induces Apoptosis in Human Cancer Cell Lines”, *RNAi Biology*, **2013**, *10*, 1–14
51. ● Pouliot, L.M.; Chen, Y.-C.; Bai, J.; **Guha, R.**; Martin, S.E.; Gottesman, M.M.; Hall, M.D.; “Cisplatin Sensitivity Mediated by WEE1 and CHK1 is Mediated by miR-155 and the miR-15 Family”, *Cancer Cell*, **2012**, *72*, 5945–5955
50. ● Pegoraro, G.; Voss, T.C.; Martin, S.E.; Tuzmen, P.; **Guha, R.**; Mistelli, T.; “Identification of Mammalian Protein Quality Control Factors by High-throughput Cellular Imaging”, *PLoS One*, **2012**, *7*, e31684
49. ● Lee, C.; Johnson, R.L.; Wichterman-Kouznetsova, J.; **Guha, R.**; Ferrer, M.; Tuzmen, P.; Martin, S.; Zhu, W.; Depamphilis, M.L.; “High-Throughput Screening For Genes That Prevent Excess DNA Replication In Human Cells And For Molecules That Inhibit Them”, *Methods*, **2012**, *57*, 234–248
48. ● Sterling, A.; Wegner, J.K.; **Guha, R.**; Bender, A.; Faulon, J.; Hastings, J.; O’Boyle, N.; Overington, J.P.; Vlijmen, H.V.; Willighagen, E.; “Cheminformatics, the Computer Science of Chemical Discovery Turning Open Source”, *Comm. ACM*, **2012**, *55*, 65–75
47. ● **Guha, R.**; “Exploring Uncharted Territories – Predicting Activity Cliffs in Structure-Activity Landscapes”, *J. Chem. Inf. Model.*, **2012**, *52*, 2181–2191
46. ● **Guha, R.**; Nguyen, D.-T.; Southall, N.; Jadhav, A.; “Dealing with the Data Deluge: Handling the Multitude of Chemical Biology Data Sources”, *Curr. Protocols Chem. Biol.*, **2012**, *4*, 193–209
45. ● Mott, B.T.; Cheng, C.C.; **Guha, R.**; Kommer, V.P.; Williams, D.L.; Vermeire, J.J.; Cappello, M.; Maloney, D.J.; Rai, G.; Jadhav, A.; Simeonov, A.; Inglese, J.; Posner, G.H.; Thomas, C.J.; “A Furoxan-Amodiaquine Hybrid as a Potential Therapeutic for Three Parasitic Diseases”, *Med. Chem. Comm.*, **2012**, *3*, 1505–1511
44. ● Heidebrecht, R.W.; Mulrooney, C.; Austin, C.P.; Barker, R.H.; Beaudoin, J.A.; Cheng, K.Chih-Chien.; Comer, E.; Dandapani, S.; Dick, J.; Duvall, J.R.; Ekland, E.H.; Fidock, D.A.; Fitzgerald, M.E.; Foley, M.; **Guha, R.**; Hinkson, P.; Kramer, M.; Lukens, A.K.; Masi, D.; Marcaurelle, L.A.; Su, X.; Thomas, C.J.; Wewer, M.; Wiegand, R.C.; Wirth, D.; Xia, M.; Yuan, J.; Zhao, J.; Palmer, M.; Munoz, B.; Schreiber, S.; “Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria”, *ACS Med. Chem. Lett.*, **2012**, *3*, 112–117
43. ● Yang, Y.; Shaffer, A.; Emre, N. C. Tolga; Ceribelli, M.; Zhang, M.; Wright, G.; Xiao, W.; Powell, J.; Platig, J.; Kohlhammer, H.; Young, R.; Zhao, H.; Yang, Y.; Xu, W.; Buggy, J.; Balasubramanian, S.; Mathews, L.; Shinn, P.; **Guha, R.**; Ferrer, M.; Thomas, C.; Waldmann, T.; Staudt, L.; “Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma”, *Cancer Cell*, **2012**, *21*, 723–737
42. ● **Guha, R.**; “Exploring Structure-Activity Data Using the Landscape Paradigm”, *WIREs Comput. Mol. Sci.*, **2012**, *2*, 829–841

Publications (continued)

41. • Mathews, L.A.; Keller, J.M.; Goodwin, B.; **Guha, R.**; Shinn, P.; Mull, R.; Thomas, C.; de Kluyver, R.; Sayers, T.; Ferrer, M.; “A 1536-well Quantitative High Throughput Screen to Identify Compounds Targeting Cancer Stem Cells”, *J. Biomol. Screen.*, **2012**, *17*, 1231–1242
40. • **Guha, R.**; Willighagen, E.L.; “A Survey of Quantitative Descriptions of Molecular Structure”, *Curr. Topics Med. Chem.*, **2012**, *12*, 1946–1956
39. • Velayati, A.; Tuzmen, P.; **Guha, R.**; Martin, S.; Goldin, E.; Sidransky, E.; “Genome-Wide RNAi Screen For Lysosomal Storage Disorders”, *Molecular Genetics and Metabolism*, **2012**, *105*, S63
38. • Yuan, J.; Cheng, K.Chih-Chien.; Johnson, R.L.; Huang, R.; Pattaradilokrat, S.; Liu, A.; **Guha, R.**; Fidock, D.A.; Inglese, J.; Wellem, T.E.; Austin, C.P.; Su, X.; “Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets”, *Science*, **2011**, *333*, 724–729
37. • Saubern, S.; **Guha, R.**; Baell, J.B.; “KNIME workflow to assess PAINS filters in SMARTS format. Comparison of RDKit and Indigo cheminformatics libraries”, *Mol. Inf.*, **2011**, *30*, 847–850
36. • O’Boyle, N.; **Guha, R.**; Willighagen, E.; Adams, S.E.; Alvarsson, J.; Bradley, J.C.; Filippov, I.; Hanson, R.M.; Hanwell, M.D.; Hutchison, G.R.; James, C.A.; Jeliaskova, N.; Lang, A.; Langner, K.M.; Lonie, D.C.; Lowe, D.M.; Pansanel, J.; Pavlov, D.; Spjuth, O.; Steinbeck, C.; Tenderholt, A.; Theisen, K.; Murray-Rust, P.; “Open Data, Open Source and Open Standards in Chemistry: The Blue Obelisk Five Years On”, *J. Cheminf.*, **2011**, *3*,
35. • **Guha, R.**; Dexheimer, T.S.; Kestranek, A.N.; Jadhav, A.; Chervenak, A.M.; Ford, M.G.; Simeonov, A.; Roth, G.P.; Thomas, C.J.; “Exploratory analysis of kinetic solubility measurements of a small molecule library”, *Bioorg. Med. Chem.*, **2011**, *19*, 4127–4134
34. • Martin, S.E.; Wu, Z.H.; Gehlhaus, K.Jones.; Zhang, Y.W.; **Guha, R.**; Miyamoto, S.; Pommier, Y.; Caplen, N.J.; “RNAi Screening Identifies TAK1 as a Potential Target for the Enhanced Efficacy of Topoisomerase Inhibitors”, *Curr. Cancer Drug Targets*, **2011**, *11*, 976–986
33. • **Guha, R.**; Wiggins, G.D.; Wild, D.J.; Baik, M.H.; Pierce, M.E.; Fox, G.C.; “Improving Usability and Accessibility of Cheminformatics Tools for Chemists Through Cyberinfrastructure and Education”, *In Silico Biol.*, **2011**, *11*, 41–60
32. • Brown, L.E.; Chih-Chien Cheng, K.; Wei, W.; Yuan, P.; Dai, P.; Trilles, R.; Ni, F.; Yuan, J.; MacArthur, R.; **Guha, R.**; Johnson, R.L.; Su, X.; Dominguez, M.M.; Snyder, J.K.; Beeler, A.B.; Schaus, S.E.; Inglese, J.; Porco, J.; “Discovery of New Antimalarial Chemotypes Through Chemical Methodology and Library Development”, *Proc. Nat. Acad. Sci.*, **2011**, *108*, 6775–6780
31. • **Guha, R.**; Gilbert, K.; Fox, G.C.; Pierce, M.; Wild, D.; Yuan, H.; “Advances in Cheminformatics Methodologies and Infrastructure to Support the Data Mining of Large, Heterogeneous Chemical Datasets”, *Curr. Comp. Aid. Drug Des.*, **2010**, *6*, 50–67
30. • Ghosh, D.; **Guha, R.**; “Use of Genetic Algorithm and Neural Network Approaches for Risk Factor Selection: A Case Study of West Nile Virus Dynamics in an Urban Environment”, *Computers, Environment and Urban Systems*, **2010**, *34*, 189–203
29. • Spjuth, O.; Willighagen, E.L.; **Guha, R.**; Eklund, M.; Wikberg, J.; “Towards interoperable and reproducible QSAR analyses: Exchange of datasets.”, *Journal of Cheminformatics*, **2010**, *2*,
28. • Chen, B.; Wild, D.; **Guha, R.**; “PubChem as a Source of Polypharmacology”, *J. Chem. Inf. Model.*, **2009**, *49*, 2044–2055

Publications (continued)

27. • Singh, N.; **Guha, R.**; Guilianotti, M.; Houghten, R.; Medina-Franco, J.L.; “Chemoinformatic Analysis of Drugs, Natural Products, Molecular Libraries Small Molecule Repository and Combinatorial Libraries”, *J. Chem. Inf. Model.*, **2009**, *49*, 1010–1024
26. • Bajorath, J.; Peltason, L.; Wawer, M.; **Guha, R.**; Lajiness, M.S.; van Drie, J.H.; “Navigating Structure Activity Landscapes”, *Drug Discov. Today*, **2009**, *14*, 698–705
25. • **Guha, R.**; Van Drie, J.H.; “Pharmacophore Representation and Searching”, *CDK News*, **2008**, ASAP
24. • **Guha, R.**; Van Drie, J.H.; “Assessing how well a modeling protocol captures a structure-activity landscape”, *J. Chem. Inf. Model.*, **2008**, *48*, 1716–1728
23. • **Guha, R.**; Van Drie, J.H.; “The Structure-Activity Landscape Index: Identifying and Quantifying Activity-Cliffs”, *J. Chem. Inf. Model.*, **2008**, *48*, 646–658
22. • **Guha, R.**; “A Flexible Web Service Infrastructure for the Development and Deployment of Predictive Models”, *J. Chem. Inf. Model.*, **2008**, *48*, 456–464
21. • **Guha, R.**; “On the Interpretation and Interpretability of QSAR Models”, *J. Comp. Aid. Molec. Des.*, **2008**, *22*, 857–871
20. • **Guha, R.**; Schürer, S.C.; “Utilizing high throughput screening data for predictive toxicology models: Protocols and application to MLSCN assays”, *J. Comp. Aid. Molec. Des.*, **2008**, *22*, 367–384
19. • Willighagen, E.L.; O’Boyle, N.; Gopalakrishnan, H.; Jiao, D.; **Guha, R.**; Steinbeck, C.; Wild, D.J.; “Userscripts for the Life Sciences”, *BMC Bioinformatics*, **2007**, *8*, 487
18. • Wang, H.; Klinginsmith, J.; Dong, X.; Lee, A.; **Guha, R.**; Wu, Y.; Crippen, G.; Wild, D.J.; “Chemical Data Mining of the NCI Human Tumor Cell Line Database”, *J. Chem. Inf. Model.*, **2007**, *47*, 2063–2076
17. • **Guha, R.**; Dutta, D.; Chen, T.; Wild, D.J.; “Counting Clusters Using R-NN Curves”, *J. Chem. Inf. Model.*, **2007**, *47*, 1308–1318
16. • Dong, X.; Gilbert, K.; **Guha, R.**; Heiland, R.; Kim, J.; Pierce, M.; Fox, G.; Wild, D.J.; “A Web Service Infrastructure for Chemoinformatics”, *J. Chem. Inf. Model.*, **2007**, *47*, 1303–1307
15. • Dutta, D.; **Guha, R.**; Chen, T.; Wild, D.J.; “Ensemble Feature Selection: Consistent Descriptor Subsets for Multiple QSAR Models”, *J. Chem. Inf. Model.*, **2007**, *47*, 989–997
14. • **Guha, R.**; “Chemical Informatics Functionality in R”, *J. Stat. Soft.*, **2007**, *18*,
13. • **Guha, R.**; Dutta, D.; Jurs, P.C.; Chen, T.; “Local Lazy Regression: Making Use of the Neighborhood to Improve QSAR Predictions.”, *J. Chem. Inf. Model.*, **2006**, *46*, 1836–1847
12. • **Guha, R.**; Dutta, D.; Jurs, P.C.; Chen, T.; “R-NN Curves: An Intuitive Approach to Outlier Detection Using a Distance Based Method”, *J. Chem. Inf. Model.*, **2006**, *46*, 1713–1722
11. • **Guha, R.**; Howard, M.T.; Hutchison, G.R.; Murray-Rust, P.; Rzepa, H.; Steinbeck, C.; Wegner, J.; Willighagen, E.L.; “The Blue Obelisk–Interoperability in Chemical Informatics.”, *J. Chem. Inf. Model.*, **2006**, *46*, 991–998
10. • Dutta, D.; **Guha, R.**; Jurs, P.C.; Chen, T.; “Scalable Partitioning and Exploration of Chemical Spaces using Geometric Hashing”, *J. Chem. Inf. Model.*, **2006**, *46*, 321–333
9. • **Guha, R.**; “Generating, Using and Visualizing Molecular Information in R”, *R News*, **2006**, *3*, 28–33

Publications (continued)

8. • Steinbeck, C.; Hoppe, C.; Kuhn, S.; Floris, M.; **Guha, R.**; Willighagen, E.L.; “Recent Developments of the Chemistry Development Kit (CDK) - An Open-Source Java Library for Chemo- and Bioinformatics”, *Curr. Pharm. Des.*, **2006**, *12*, 2110–2120
7. • **Guha, R.**; Stanton, D.T.; Jurs, P.C.; “Interpreting Computational Neural Network QSAR Models: A Detailed Interpretation of the Weights and Biases”, *J. Chem. Inf. Model.*, **2005**, *45*, 1109–1121
6. • **Guha, R.**; Jurs, P.C.; “Interpreting Computational Neural Network QSAR Models: A Measure of Descriptor Importance”, *J. Chem. Inf. Model.*, **2005**, *45*, 800–806
5. • **Guha, R.**; Jurs, P.C.; “Determining the Validity of a QSAR Model—A Classification Approach”, *J. Chem. Inf. Model.*, **2005**, *45*, 65–73
4. • **Guha, R.**; “Using R to Provide Statistical Functionality for QSAR Modeling in CDK to Provide Statistical Functionality for QSAR Modeling in CDK”, *CDK News*, **2005**, *2*, 7–13
3. • **Guha, R.**; Jurs, P.C.; “Development of Linear, Ensemble, and Nonlinear Models for the Prediction and Interpretation of the Biological Activity of a Set of PDGFR Inhibitors.”, *J. Chem. Inf. Comput. Sci.*, **2004**, *44*, 2179–2189
2. • **Guha, R.**; Jurs, P.C.; “The Development of QSAR Models To Predict and Interpret the Biological Activity of Artemisinin Analogues”, *J. Chem. Inf. Comput. Sci.*, **2004**, *44*, 1440–1449
1. • **Guha, R.**; Serra, J.R.; Jurs, P.C.; “Generation of QSAR Sets with a Self-Organizing Map.”, *J. Mol. Graph. Model.*, **2004**, *23*, 1–14

Books and Book Chapters

- **Guha, R.**; Das, S.; “Exploring the Role of Small Molecules in Biological Systems Using Network Approaches” in *Computational Network Analysis with R*, Eds. Dehmer, M.; Shi, Y.; Emmert-Streib, F.; Wiley-VCH Verlag GmbH; **2016**; pp. 151–172
- **Guha, R.**; “On Exploring Structure Activity Relationships” in *In silico Models for Drug Discovery*, Ed. Kortegere, S.; Humana Press; **2013**; pp. 81–94
- **Guha, R.**; Bender, A. (Eds.); *Computational Approaches in Cheminformatics and Bioinformatics*; John Wiley & Sons, New York.; **2012**
- **Guha, R.**; “Collaborative Cheminformatics Applications” in *Collaborative Computational Technologies for Biomedical Research*, Eds. Eakins, S., Hupcey, M.A.Z., Williams, A.J.; Wiley, New York; **2011**; pp. 399–422
- **Guha, R.**; “The Ups and Downs of Structure-Activity Landscapes” in *Cheminformatics and Computational Chemical Biology*, Eds. Bajorath, J.; Springer, Berlin; **2011**; pp. 101–107
- **Guha, R.**; “Open Source Cheminformatics Software & Database Technologies” in *A Handbook of Cheminformatics Algorithms*, pp. 343–362, Faulon, J.-L.; Bender, A. (Eds.); Chapman & Hall/CRC, Boca Raton, FL; **2010**
- Ghosh, D.; **Guha, R.**; “A Risk Factor Analysis of West Nile Virus: Extraction of Relationships from a Neural Network Model” in *Advances in Social Computing, Proc. 3rd Intl. Conf. Social Computing, Behavioral Modeling and Prediction, SBP 2010*; Eds. Chai, S.-K.; Salerno, J.J.; Mabry, P.L.; Springer, Berlin; **2010**

Books and Book Chapters (continued)

- Bradley, J.C.; **Guha, R.**; Lang, A.; Lindenbaum, P.; Neylon, C.; Williams, A.; Willighagen, E.; “Beautifying data in the real world” in *Beautiful Data - The Stories Behind Elegant Data Solutions*, Segaran, T.; Hammerbacher, J. (Eds.), O’Reilly and Associates, **2009**
- Fox, G.C.; **Guha, R.**; McMullen, D.F.; Mustacoglu, A.F.; Pierce, M.; Topcu, A.E.; Wild, D.J.; “Web 2.0 for Grids and e-Science” in *Proc. INGRID 2007 - Instrumenting the Grid*, **2008**

Invited Presentations

- April 2017 • Talk titled *Pharos A Torch to Use in Your Journey In the Dark Genome* at the BD2K-LINCS Data Science Research Webinar Series.
- October 2016 • Talk titled *Enhancing Prioritization & Discovery of Novel Combinations using an HTS Platform* at the 7th American Conference on Pharmacometrics, Bellevue, WA.
- September 2016 • Talk titled *Expanding the Dimensionality of Screening: From Single Agent Libraries to a Combination Screening Platform* at Merck Laboratories, Boston, MA.
- August 2016 • Talk titled *What can your library do for you?* at the ACS National Meeting, Philadelphia, PA.
- September 2015 • *Exploring & Quantifying Compound Combinations in High Throughput Settings: Going Beyond 1D Metrics* at MipTec, Basel, Switzerland.
- August 2015 • *Characterization of Chemical Libraries Using Scaffolds and Network Models* at the ACS National Meeting, Boston, MA.
- August 2015 • *So I have an SD File ... What do I do next?* at the ACS National Meeting, Boston, MA.
- July 2015 • *Multidimensional descriptors, multidimensional responses: Computational challenges facing QSAR* at Gordon Research Conference, CADD, Mt Snow, VT.
- February 2015 • *From Data to Action: Bridging Chemistry and Biology with Informatics at NCATS* at Georgetown University, Washington D.C.
- June 2014 • *Exploring Combinations in High throughput Settings* at Novartis, Boston, MA.
- March 2014 • *When the Whole is Better than the Sum – Analytics to Support High Throughput Combination Screening* at Advancing Computational Biology Symposium, Howard University, Washington D.C.
- January 2014 • *Exploring Compound Combinations in High Throughput Settings: Going Beyond 1D Metrics* at SLAS, San Diego, CA.
- December 2012 • *Data Driven Discovery in Chemistry and the Tools to Enable It* at CSIR, New Delhi, India.
- December 2012 • *Predicting Biological Activity from Molecular Structure* at Presidency University, Kolkata, India.
- September 2012 • *Cloudy, with a touch of cheminformatics* at the ChemAxon UGM, Boston, MA.
- June 2012 • *Chemogenomics in the cloud. Is the sky the limit?* at Translational Bioinformatics in the Cloud, New Brunswick, NJ.
- January 2012 • *Clustering and Classification to identify Hits in High Content RNAi Screens* at CHI High Content Analysis, San Francisco, CA.
- September 2011 • *Smashing Molecules* at the Chemaxon UGM, San Diego, CA.
- August 2011 • *Predicting Activity Cliffs - Can Machine Learning Handle Special Cases?* at the Joint Statistical Meeting, Miami Beach, FL.
- May 2011 • *R & CDK: A Sturdy Platform in the Oceans of Chemical Data* at the Molecular Informatics Open Source Software, EBI, Hinxton, UK.

Invited Presentations (continued)

- May 2011 • *Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the NCTT at the ChEMBL group, EBI, Hinxton, UK.*
- May 2011 • *Enabling Discoveries at High Throughput - Small molecule and RNAi HTS at the NCTT at Syngenta, Jealotts Hill, UK.*
- March 2011 • *Structure-Activity Relationships and Networks: A Generalized Approach to Exploring Structure-Activity Landscapes at George Mason University, Fairfax, VA.*
- January 2011 • *High throughput, High Content Screening - Enhancing Throughput via Fragments and Automation at Howard University, Washington D.C.*
- January 2011 • *High Throughput, High Content Screening - Automating the Pipeline at CHI High Content Analysis, San Francisco, CA.*
- November 2010 • *Chemical IR Workshop at TREC 2010, NIST, Gaithersburg, MD.*
- February 2010 • *Joining the Dots: Integrating High Throughput Small Molecule and RNAi Screens at the CCMB Seminar Series, University of Michigan, Ann Arbor, MI.*
- January 2010 • *Prioritizing Scaffolds for Hit Selection in High Throughput Screening at the 6th Indo-US Workshop on Mathematical Chemistry at Kolkata, India.*
- December 2009 • *Molecular Representation, Similarity and Search, guest lecture at Drexel University.*
- August 2009 • *Crunching Molecules and Numbers in R at the 238th ACS National Meeting at Washington, D.C.*
- April 2009 • *Open Source Cheminformatics: Tools and Data at BioIT World, Boston, MA.*
- February 2009 • *Structure-Activity Relationships and Networks: A Generalized Approach to Exploring Structure-Activity Landscapes at the Ontario Institute for Cancer Research, Toronto.*
- December 2008 • *Networks - More Than Just Pretty Pictures at Vertex Pharmaceuticals, Cambridge, MA.*
- December 2008 • *A Network View of Structure-Activity Landscapes at Drexel University, Philadelphia, PA.*
- December 2008 • *Networks - More Than Just Pretty Pictures at the CGB Roundtable, Indiana University, Bloomington. IN.*
- October 2008 • *Structure-Activity Relationships and Networks: A Generalized Approach to Exploring Structure-Activity Landscapes at the NIH Chemical Genomics Center, Rockville, MD.*
- August 2008 • *Defining and Using Structure Activity Landscapes at Simulations Plus, Lancaster, CA.*
- June 2008 • *Numerical Characterization of Structure-Activity Relationships from a Medicinal Chemist's Point of View at the 31st National Medicinal Chemistry Symposium, Pittsburgh, PA.*
- May 2008 • *Aspects of Model Quality & Applicability at Pfizer Inc., Groton, CT.*
- March 2008 • *The Structure Activity Landscape Index: Visualization and Applications at Eli Lilly & Co., Indianapolis, IN*
- January 2008 • *Characterizing and Utilizing Structure Activity Landscapes at Abbott Laboratories, Chicago, IL.*
- August 2007 • *Characterizing the Density of Chemical Spaces and its Use in Outlier Analysis and Clustering at the Novartis Institute for Biomedical Research, Cambridge, MA.*

Invited Presentations (continued)

- May 2007 • *The Development and Deployment of Predictive Toxicology Models* at the MLSCN Steering Committee Meeting, Philadelphia, PA.
- February 2007 • *Making the Most of Predictive Models* at the Openeye Cup 8, Santa Fe, NM.
- January 2007 • *The Role of the Neighborhood in QSAR Modeling and Cheminformatics* at the Dept. of Pharmaceutical Technology, Jadavpur University, Calcutta.
- August 2006 • *Chemical Spaces: Modeling, Exploration & Understanding* at the CICC-MACE-Lilly Cheminformatics Workshop, Indianapolis, IN.
- August 2006 • *Writing & Using Web Services* at the CICC-MACE-Lilly Cheminformatics Workshop, Indianapolis, IN.
- April 2006 • *Navigating Molecular Haystacks: Tools & Applications* at the School of Informatics, Indiana University, Bloomington, IN.
- March 2006 • *Computational Tools & Protocols For Drug Discovery* at the School of Pharmacy, University of Maryland, Baltimore, MD.
- September 2005 • *Extending Validation and Providing Interpretability for QSAR Models* at the Jet Propulsion Laboratory, Pasadena, CA.
- February 2005 • *The Validation and Interpretation of QSAR Models* at NCI, Frederick.